The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

Chronic kidney disease (CKD) is a progressive renal disease that causes kidney function to deteriorate. It appears as urinary ...

Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

More than 35 million people in the U.S. have chronic kidney disease (CKD), a condition in which the kidneys are damaged and ...

The FDA has approved popular antiobesity drug Ozempic to help protect patients with type 2 diabetes from kidney disease.

A recent modeling study has identified risk factors predictive of good and bad outcomes in non-diabetic CKD, such as gender, ...

The burden is particularly high in urban areas, where the prevalence reaches 15.2 percent compared to just 2.0 percent in ...

A retired Chicago firefighter who was honored by the state for the lives he saved during his 30-year career is now in desperate need of a kidney.

Patients with CKD who use antiresorptive drugs for tumor-related disorders or oral corticosteroids may be at increased risk for osteonecrosis of the jaw.

The burden is particularly high in urban areas, where the prevalence reaches 15.2 percent compared to just 2.0 percent in ...

The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...